A Two-Part Randomized Double-Blinded Placebo-Controlled, Phase 1 Study of Single and Multiple Ascending Doses of MH-001 in Healthy Participants
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs MH 001 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Vespina Lifesciences
- 23 Jan 2025 New trial record